Health AI Central
Share:
Peer-Reviewed Publication
Biomark Insights2023;1811772719231178618.January 1, 2023Journal Article

Implementation of a Customized Tertiary Analysis Platform for the Reporting of Somatic Variants.

Kala F Schilter1, Sarah Dubay2, Matt Stachowiak2, Alysia Kaplan2, Abby Stauffenger2, Honey V Reddi1
1Precision Medicine Laboratory, Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA.
2GenomOncology, Cleveland, OH, USA.
PubMed PMC DOI PDF

Abstract

Precision medicine for oncology requires the evaluation of variants identified in molecular profiling of solid tumors and hematologic malignancies. This includes evaluation of pre-analytical and postanalytical quality metrics, variant interpretation, classification, and tiering as outlined in established guidelines, association with clinical significance such as FDA approved drugs and clinical tri…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.